Relapsed Acute Myeloid Leukemia

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Imetelstat Combinations in Relapsed AML

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia